Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial (EF-14) (2017)

Peer-Reviewed Study · Stupp R, Taillibert S, Kanner A, et al. · December 19, 2017

Stupp R et al., 2017-12-19: Final analysis of the EF-14 randomised trial: 695 patients, 2:1 to TTFields plus temozolomide or temozolomide alone; median overall survival 20.9 vs 16.0 months and progression-free survival 6.7 vs 4.0 months.

Median overall survival was 20.9 months in the TTFields-temozolomide group vs 16.0 months in the temozolomide-alone group (HR, 0.63; 95% CI, 0.53-0.76; P < .001).

Abstract, Results (JAMA 318(23):2306-2316)

Stupp R et al., 2017-12-19: Final analysis of the EF-14 randomised trial: 695 patients, 2:1 to TTFields plus temozolomide or temozolomide alone; median overall survival 20.9 vs 16.0 months and progression-free survival 6.7 vs 4.0 months. Open-label, 83 centres, enrolled 2009-2014. Four authors are Novocure employees (Kirson ED, Lavy-Shahaf G, Weinberg U, Palti Y), and the trial was sponsored by Novocure Ltd, the device maker – a material conflict to record. Comparator: temozolomide alone (active control), randomised 2:1. An erratum (JAMA 2018;319(17):1824) and two 2018 comment letters exist. Preliminary 2015 report: PMID 26670971 (same trial – do not count as independent evidence). Study type: randomized trial.